© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > BMS-986260
<< Back to February
selective TGFβR1 kinase inhibitor
completed oral CV studies in higher species
from data mining of internal matter and opt.
ACS Med. Chem. Lett. 11, 172-178
Bristol-Myers Squibb, Princeton, NJ
BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)
Unlock this content with a Premium membership to read it now.